MA-EVALUATE
4.6.2019 14:02:06 CEST | Business Wire | Press release
The $1.18tr forecast for the 2024 global prescription drug market reflects the role new technologies will play in addressing unmet medical needs, as strong expectations for immuno-oncology products and emerging cell and gene therapies drive growth. In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and the projected CAGR of 6.9% from 2019-2024 significantly outpaces the 2.3% CAGR seen from 2010-2018.
Growth Drivers:
- 2018 saw 62 FDA approvals for novel drugs, an increase over the 55 approvals in 2017
- Oncology therapies to reach $237bn in 2024, with a CAGR of 11.4%
- Orphan Drugs will contribute an additional $109bn in sales in 2024, compared to 2018
However, as more new technologies reach the market, drug pricing pressure may continue to intensify and dampen the overall sales outlook. R&D spending is also forecast to grow more slowly from 2019-2024 than in prior years, and decrease as a proportion of overall sales – a sign of either increasing R&D efficiency, or of companies focusing on smaller indications with lower clinical development costs.
Growth Brakes:
- $198bn in sales are at risk between 2019 and 2024, due to patent expirations
- Anti-rheumatics sales decline as Humira, Enbrel and Remicade face competition
- R&D as a proportion of prescription sales is forecast to decline from 21.6% in 2018 to 18% in 2024
“Scientific advancements and health technologies are converging to deliver new options for patients, while challenging traditional drug development and commercialisation models,” said report author Ryan Waters. “The question is, which companies are best poised to take advantage of the evolving pharmaceutical market?”
Top Performers:
- Pfizer will be the leading prescription drug company in 2024, with projected sales of $51.2bn
- Keytruda is forecast to be the top selling drug in 2024, as Humira slips in the face of biosimilars
- Johnson & Johnson overtakes Roche to be the biggest spender on pharmaceutical R&D in 2024
Download your complimentary copy of the “EvaluatePharma® World Preview 2019, Outlook to 2024” at https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024 , or visit us at Booth #2243 at the BIO International Convention, June 3-6, in Philadelphia, PA.
About Evaluate Ltd.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. Our EvaluatePharma® and EvaluatePharma Vision online subscription services provide a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com .
Follow us on Twitter: @EvaluatePharma, @Vantageanalysis
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604005091/en/
Contact:
Media Contact: Evaluate and Vantage Jennifer Dinkel +1 617-936-7783 jennifer.dinkel@evaluate.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sihoo præsenterer næste generation af ergonomiske kontorløsninger på ORGATEC 202620.10.2026 20:12:00 CEST | Pressemeddelelse
Med ORGATEC 2026 lige om hjørnet vil Sihoo, specialist i ergonomiske sidde løsninger, præsentere sine næste generations løsninger til arbejdspladsen i hal 8.1, stand A-060 og B-061. I tråd med messens tema, »Fra rum til relationer: design af rum i en verden i konstant forandring«, vil Sihoo demonstrere, hvordan adaptivt ergonomisk design understøtter skiftende siddestillinger og nye behov på moderne arbejdspladser. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261020048673/da/ Sihoo på ORGATEC 2026 i Köln En oplevelseszone baseret på forskellige arbejdsscenarier Sihoos stand har et åbent layout, hvor en orange-hvid farvepalet kombineres med loftskonstruktioner i flere niveauer, halvgennemsigtige skillevægge og integreret belysning. Arbejdsstationer med højdejusterbare skriveborde og skærme samt siddeområder til samarbejde genskaber velkendte kontormiljøer og viser, hvordan ergonomiske stole passer ind på moderne arbejdspl
FPT and the Niels Bohr Institute Advance Vietnam–Denmark Collaboration in Quantum Talent Development20.10.2026 20:07:00 CEST | Press release
In the presence of H.E. Tô Lâm, General Secretary of the Communist Party of Vietnam and President of Vietnam, and His Majesty King Frederik X of Denmark, FPT Corporation, Vietnam's leading technology corporation operating in 31 countries and territories, and the Niels Bohr Institute (NBI), University of Copenhagen, one of the world's leading quantum research institutions, exchanged a Memorandum of Understanding (MoU) to strengthen collaboration in quantum science and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019899787/en/ General Secretary of the Communist Party of Vietnam Central Committee and President To Lam, Danish King Frederik X and delegates at the Vietnam–Denmark Business Forum in Copenhagen on October 20. (Photo: VNA) The partnership aims to strengthen scientific cooperation between Vietnam and Denmark by connecting Vietnamese researchers with one of the world's foremost centers for quantum resea
Grafana Labs Charts the Path to Agentic Operations with Watchers, Pages, and Agent Observability at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Grafana Labs delivers AI for observability and observability for AI: always-on agents to operate systems, and OpenTelemetry-native visibility into the agents you ship Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that move Grafana Cloud towards agentic operations, including the general availability of Agent Observability with OpenTelemetry support and of Assistant Watchers, and previews of Grafana Pages and Grafana Managed Sandboxes. As AI moves into production, teams face two connected challenges: using agents to operate their systems and understanding the behavior of the agents themselves. In the 2026 State of Observability Report, also released this week by Grafana Labs and ETR, a Futurum company, 68% of the 300 IT and engineering leaders surveyed have moved AI for observability past investigation into pilots or production. But confidence depends on the task and readiness varies: 85% report comfort with r
Grafana Labs Brings Faster Full-text Search and Smarter Data Optimization to Grafana Cloud at ObservabilityCON 202620.10.2026 19:00:00 CEST | Press release
Adaptive Logs Archive lets teams keep more logs for less, and faster queries for rare values in Grafana Cloud Logs help them, and their agents, find what matters in seconds Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that help teams manage their telemetry in the AI era, finding the right log line in seconds and keeping only the telemetry worth paying for as AI workloads scale. Major query performance enhancements to Grafana Cloud Logs, built on technology from the company's Logline acquisition, are now generally available, and Adaptive Logs Archive is in public preview. AI is massively increasing telemetry volumes. Coding agents are turning everyone into a developer, so more software is being built, faster, and all of it needs to be watched. The agents add to the load too, since every agent call and tool call emits its own telemetry. Left alone, observability costs grow with every new workload, which makes
Nissan Technical Centre Europe Adopts Sonatus Fastlane™ Platform to Accelerate Vehicle Test and Validation20.10.2026 18:37:00 CEST | Press release
Event-driven data collection and AI-powered root-cause analysis to become standard practice for new NTCE vehicle programs; Proven to cut investigation time from two weeks to two days Following a successful proof of concept and ongoing engineering development over the past 12 months, Nissan Technical Centre Europe (NTCE), Nissan’s primary R&D hub for its global regions, is expanding its use of the Sonatus® Fastlane™ Platform across its pre-start-of-production (SOP) validation workflow. The platform’s event-driven data collection and root-cause analysis have reduced the time NTCE engineers spend investigating vehicle software issues from two weeks to two days. NTCE plans to make the platform a standard part of validating future vehicle programs, including upcoming models such as the Nissan JUKE. With the Fastlane Platform, engineers have the data they need from the moment a fault occurs. Teams deploy targeted data-collection policies from the cloud, and capture begins automatically when
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom